Keytruda® (pembrolizumab) – Updated indication
August 31, 2021 - Merck announced the FDA approval of Keytruda (pembrolizumab), for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy.
Download PDF
